Replies to post #385002 on Innovation Pharmaceuticals Inc (IPIX)

[warrenthomas4001]

I believe so, and as a potent antiviral in early stage or mild disease while viral load is building, antecedent to widespread cell and cell nucleus damage. There’s a “sweet spot” somewhere within the line of progression between pre-exposure, incubation, presentation and end-stage disease, where a drug can yield best (if any) results. In vitro data was obviously sufficiently convincing to RBL AND FDA to garner attention, so there’s surely some “there” there… it’s just a matter of, where’s there?

[farrell90]

Brilacidin's virucidal MOA against Coronavirus is unique. To the best of my knowledge Brilacidin is the only drug whose in vitro clinical studies demonstrate a virucidal action against covid 19.

Most other drugs just demonstrate 1 MOA. Brilaidin's 3 anti viral MOA: virucidal,prevention of viral entry and the possible effect against intracellular viral replications by inhibiting the viral m- Protein as shown in the computer modeling study suggest it is possible Brilacidin could lose 1 MOA and still be effective.

The conclusion of the Wang paper was that Brilaidin did block the coronavirus viral entry by 2 mechanism of action, viral and cellular.

GLTA,Farrell